Ionis Q2 adjusted operating loss narrows

Ionis Pharmaceuticals

29/07/2026 12:16

Overview
RNA medicines developer's Q2 adjusted operating loss narrows
Q2 commercial revenue rose 15% yr/yr, driven by DAWNZERA product sales
Higher Q2 operating expenses due to commercialization and launch investments

Outlook
Company expects full-year 2026 TRYNGOLZA product sales of $100-110 mln
Ionis expects full-year 2026 DAWNZERA product sales of $110-120 mln
Company says it remains on track to achieve 2026 financial guidance

Result Drivers
NEW PRODUCT LAUNCHES - Co said early launch momentum for TRYNGOLZA in severe hypertriglyceridemia and strong DAWNZERA sales drove commercial revenue growth
COMMERCIALIZATION INVESTMENTS - Higher operating expenses mainly due to investments in commercialization efforts for TRYNGOLZA, DAWNZERA, and launch preparations for zilganersen
R&D COLLABORATIONS - Growth in research and development revenue attributed to multiple payments for advancing programs under R&D collaborations, excluding prior-year one-time payment

Company press release: ID:nBw6cVFzRa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$115 mln
 
Q2 Adjusted Operating Income
Beat
-$57 mln
-$178.43 mln (15 Analysts)
Q2 Adjusted Operating Expenses
 
$325 mln
 
Q2 Operating Expenses
 
$370 mln
 
Q2 Operating Income
 
-$102 mln
 

Reuters Recommended Reads
July 28 - Incyte beats Q2 revenue estimates on strong product demand
July 29 - Biogen Q2 revenue beats expectations on strong product demand
July 27 - Argenx to buy Forte Biosciences for about $2.2 billion

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)